The immunogenicity of heat-inactivated varicella vaccine and effects on VZV pathogenesis were evaluated in 75 BMT patients randomized to receive vaccine or no intervention. Among 14 patients given a single dose at 1 month after transplantation, the mean ({SE) stimulation index (SI) was 12.20 { 3.13 compared with 4.83 { 2.74 (P Å .036) in 14 unvaccinated patients, but clinical disease was not altered. Among 24 patients vaccinated at 1, 2, and 3 months, mean SI was 8.43 { 3.89 versus 2.00 { 0.33 (P Å .014) in 23 unvaccinated patients at 4 months and 8.56 { 2.81 versus 5.30 { 2.47 (P Å .043) at 5 months. Disease severity associated with VZV reactivation was decreased dramatically in vaccinees given three doses; severity scores were 6.4 { 1.0 versus 11.8 { 1.1 (P Å .007). This experience with varicella vaccine in BMT patients is the first evidence that active immunization can reduce morbidity due to herpesvirus reactivation in high-risk populations.
Impaired cellular immunity to varicella zoster virus (VZV)
but severe morbidity occurs, especially in patients with cranial nerve involvement, and postherpetic neuralgia is not prevented in immunocompromised patients and otherwise healthy elderly persons correlates with an increased risk of reactivation of the [12, 13] . The live attenuated varicella vaccine protects against varivirus from sites of latency in dorsal root ganglia [1 -4] . Clinically, VZV reactivation causes herpes zoster. The incidence of cella, which is caused by primary VZV infection [14, 15] . Our hypothesis was that immunization with a heat-killed preparaherpes zoster in bone marrow transplant (BMT) recipients ranges from 23% to 50% during the first year, with most epition of the varicella vaccine could substitute for the ''natural'' resensitization caused by VZV reactivation after BMT and that sodes occurring within the first 2 -10 months [1, 5 -11] . This high frequency of VZV reactivation in BMT recipients proearly restoration of immunity would modify the pathogenesis of recurrent VZV disease. vided an opportunity to investigate the basic immunobiology of herpesvirus infection by assessing the impact of vaccineinduced reconstitution of virus-specific host responses. T cell recognition of VZV proteins is recovered gradually after BMT Methods [2, 3] . Nevertheless, the reconstitution of VZV immunity is delayed for months and often does not occur until after the Study population. Patients scheduled to undergo autologous patient has experienced an endogenous reexposure to VZV BMT or peripheral blood stem-cell infusion, or allogeneic or matched unrelated donor BMT, at Stanford University Medical antigens associated with clinical disease or, in some cases, with
Center, who were 18-49 years old, and who had leukemia or subclinical reactivation [1 -3, 9] . Acyclovir therapy controls lymphoma were eligible to participate (table 1) . Other enrollment most life-threatening VZV complications in BMT recipients, criteria included serologic evidence of VZV infection before transplantation, no history of herpes zoster, and no exposures to VZV or other immunizations during the first month after BMT. Standardized preparative regimens were given before BMT. Random- 4.5 U/0.5 mL; it was stored at 070ЊC, reconstituted with diluent as evaluated by the patient, was scored as follows: none Å 0, mild Å 1, moderate Å 2, severe Å 3. The requirement for acyclovir (lot 1291V), and given by subcutaneous injection (0.5 mL/dose).
Study design. In the first protocol, a single dose of vaccine therapy, as prescribed by the patient's physician, was scored as follows: oral therapy only Å 1, oral and intravenous therapy Å 2. was given 1 month after BMT. The second protocol evaluated a three-dose regimen with vaccination at 1, 2, and 3 months after Postherpetic neuralgia was defined as pain persisting after resolution of cutaneous disease. BMT. Patients were enrolled in the single-dose protocol during 1993 and in the three-dose protocol during 1994-1995. A standard Assays for VZV immunity. Participants in the single-dose study were tested for T cell immunity to VZV antigen and for VZV IgG form was used to record symptoms during the first 21 days after vaccination, including temperature, pain, rash, and other events.
antibodies at 1, 2, 3, and 12 months after BMT; those in the three-dose study were also evaluated at 4 and 5 months. Patients Acyclovir was administered to patients at the time of herpes simplex virus outbreak, but prophylactic therapy was not given. Intrareceiving vaccine provided blood samples prior to immunization. T cell proliferation and VZV IgG antibodies were measured during venous ganciclovir and intravenous immune globulin were given prophylactically to allogeneic transplant recipients for 3 months episodes of herpes zoster and 1-2 months later when possible. T cell recognition of VZV antigen was determined by incubating peripheral after transplantation and to all patients with human cytomegalovirus (HCMV) disease.
blood mononuclear cells (PBMC) (3 1 10 5 cells/well) with dilutions of VZV-infected cell extract (1:16-1:256), uninfected cell control, Patients were monitored for clinical signs of VZV reactivation for 12 months after BMT. Unusual rashes and varicella or zosteror phytohemagglutinin, in RPMI medium with 10% human serum for 5-6 days [16] . Proliferation was detected by tritiated thymidine like lesions were evaluated by the patient's physician; herpes zoster was diagnosed by the clinical presentation of a localized, vesicular uptake. The stimulation index (SI) was calculated as the ratio of mean counts per minute in antigen-stimulated wells to mean counts in rash with a dermatomal distribution, Tzanck or direct immunofluorescence stain of cells from lesions, or viral culture. Clinical control wells. The phenotypes of T cells from PBMC cultures stimulated with whole VZV antigen (1:64 dilution) were assessed by cytodisease was assessed with parameters used to quantitate the efficacy of antiviral drugs in patients with herpes zoster [12] . The fluorometry after staining with CD4, CD8, and CD16 monoclonal antibodies (Becton Dickinson, San Jose, CA). severity of herpes zoster was scored numerically according to the sum of disease manifestations as follows: fever ú37.8ЊC: no Å 0, Production of interferon-g (IFN-g), interleukin-4 (IL-4), and IL-10 was assessed after stimulation with VZV antigen (1:64 diluyes Å 1; extent of rash: £25 lesions Å 1, 26-100 lesions Å 2, 101-250 lesions Å 3, ú250 lesions Å 4; persistence of new lesion tion) for 5-6 days when sufficient numbers of PBMC were obtained. Supernatant samples were tested in duplicate for each cytoformation: £7 days Å 1, 8-14 days Å 2, 15-21 days Å 3, §22 days Å 4; time to complete crusting: £7 days Å 1, 8-14 days Å kine. IFN-g and IL-10 were detected by EIA (Endogen, Cambridge, MA), and IL-4 was assessed by use of an ultrasensitive 2, 15-21 days Å 3, §22 days Å 4. Cutaneous dissemination was defined as §6 lesions outside the primary dermatome. Acute pain, assay (Cytoscreen; Biosource, Camarillo, CA).
/ 9d31$$se30 07-10-97 12:46:04 jinfa UC: J Infect had no episodes of herpes zoster during the year following transplantation than for those patients who experienced symptomatic VZV reactivation; the mean SIs were 18.60 { 3.39 and 5.80 { 2.60 (P Å .065), respectively. In contrast, the mean SIs at 3 months after BMT among unvaccinated patients were equivalent in those who did not develop herpes zoster and in those who did; the mean SIs were 5.63 { 3.52 and 2.05 { 0.45 (P Å .50), respectively. Vaccine recipients who developed herpes zoster had evidence of immunologic priming of cell-mediated immunity. The mean T cell proliferation to VZV antigen measured after resolution of acute herpes zoster was 48.2 { 19.89 in vaccinees compared with 13.5 { 5.8 (P Å .05) in unvaccinated patients. Among the vaccinated patients, the mean SI 1 year after transplantation was 80.86 { 41.72 in vaccinees (n Å 5) who had experienced herpes zoster compared with 7.63 { 2.14 (P Å .021) in vaccinated patients (n Å 3) who had not. The mean SI at 1 year was also higher in unvaccinated patients who developed herpes zoster (n Å 3) than in those patients who did not (n Å 6), but the difference was not significant; the mean SIs were 17.10 { 5.83 and 5.83 { 1.66 (P Å .07), respectively. were not significantly different between vaccinated and unvaccinated patients, and sequential titers did not vary ú4-fold in individual patients. VZV IgG titers were not predictive of the VZV IgG antibodies were measured by ELISA [16] by VZV reactivation between the vaccinated and unvaccinated was used to estimate the probability of developing herpes zoster, patients. The mean severity scores were 11.0 { 1.8 and 8.4 { based on the SI measure at 3 months. Disease severity for cohort 0.6, respectively (P Å .17).
comparison was determined by the sums of each patient's severity
The 5 vaccinated patients who developed herpes zoster during score within the cohort.
the first year had VZV reactivation 4-7 months after transplantation. The incidence of herpes zoster was 56% among the 9 vacciResults nated patients who survived for at least 12 months; 4 of 8 autologous transplant patients and the 1 surviving allogeneic transplant Immunogenicity of the single-dose regimen. Patients who were immunized with a single dose of inactivated varicella vacpatient developed herpes zoster. Four of the 14 unvaccinated patients developed herpes zoster within 2-12 months, and 1 cine given at 1 month after transplantation achieved earlier recovery of cell-mediated immunity to VZV than did unvaccinated patient had reactivation at 18 months. Of the 11 unvaccinated patients who survived for at least 1 year, 2 of 7 autologous patients. The mean ({SE) SI at 3 months after BMT was 12.20 { 3.13 among vaccinated patients compared with 4.83 { 2.74 transplant patients and 1 of 4 allogeneic BMT recipients developed herpes zoster during the first year. Among the 16 study (P Å .036) among unvaccinated patients ( figure 1) .
Among the vaccinated patients, the mean SI at 3 months participants who survived for 2 years, 1 unvaccinated patient developed herpes zoster between 12 and 24 months. after BMT was higher for those patients who subsequently / 9d31$$se30 07-10-97 12:46:04 jinfa UC: J Infect pared with concentrations at 1 month. IL-4 production by PBMC stimulated with VZV antigen was not detected in PBMC from vaccinated or unvaccinated patients, which is consistent with the absence of IL-4 responses to VZV antigen in otherwise healthy persons (Redman R, Arvin A, unpublished data). IL-10 production to VZV antigen was detected consistently in PBMC cultures from vaccinated and unvaccinated patients at mean concentrations of ú100 pg/mL during the first 12 months; IL-10 concentrations did not change significantly in relation to the interval after transplantation. While mean concentrations did not differ among patient groups, production of IFN-g and IL-10 was significantly higher among patients who had recovered T cell proliferation to VZV antigen. The mean IFN-g concentration was 158 pg/mL { 32.83 in those with SIs §2.0 compared with 69 pg/mL { 24.80 (P Å .03) in patients with no detectable T cell proliferation to VZV antigen, and the mean IL-10 concentration was 175 pg/mL { 20.42 in patients who had recovered T cell responses compared with 117 pg/mL { 17.70 (P Å .04) in those who had not. After short-term stimulation of PBMC from BMT patients with VZV antigen, the mean percentages of CD4 T cells ranged were 15.15 { 4.62 in vaccinees and 9.38 { 4.62 in unvaccinated patients (P Å .389) (figure 2). Recovery of T cell recognition of VZV antigen (SI §2.0) was documented in 83% of Assessment of T cell proliferation to VZV antigen showed that BMT recipients could respond to inactivated varicella vacvaccinees and 77% of unvaccinated patients. A linear correlation between T cell proliferation to VZV antigen and IFN-g cine given 1 month after transplantation, but the failure of a single dose of vaccine to alter clinical disease provided the production was observed at 1 year after BMT (P õ .001; correlation coefficient Å .81). rationale for evaluating a multidose regimen.
Immunogenicity of the three-dose regimen. Administration No correlations were observed between VZV IgG titers and the incidence of herpes zoster among participants in the threeof vaccine at 1, 2, and 3 months after transplantation elicited early recovery of T cell responses to VZV (figure 2). The mean dose study. VZV IgG antibody titers were equivalent in vaccinated and unvaccinated patients (range, 1:64 -1:262,144). SIs to VZV antigen were higher in vaccinated patients by 3 months after BMT, and the differences in mean SIs between Clinical efficacy of the three-dose regimen. The incidence of herpes zoster during the first year after transplantation was vaccinated and unvaccinated patients were significant by 4 and 5 months after transplantation. The mean SI was 8.43 { 3.89 23% (5/22) in vaccinated patients and 22% (5/23) in unvaccinated participants, but the clinical disease among vaccinated in vaccinees compared with 2.00 { 0.33 (P Å .014) in unvaccinated patients at 4 months and 8.56 { 2.81 in vaccinees compatients was markedly less severe (table 3) . The mean severity score was 6.4 { 1.0 in vaccinees compared with 11.8 { 1.1 pared with 5.30 { 2.47 (P Å .043) in unvaccinated patients at 5 months after BMT. The mean increase in T cell proliferation in patients who were not immunized (P Å .007). The interval to disease occurrence was 4 -8 months among at 4 and 5 months after transplantation relative to the baseline response of each patient measured at 1 month was significantly vaccinated patients. The incidence of herpes zoster was 29% among 17 vaccinees who survived for §12 months. Eleven of greater among vaccinees (P Å .01 at 4 months; P Å .02 at 5 months).
12 autologous transplant patients survived for at least 1 year; 1 patient developed herpes zoster. Five of 8 vaccinees who Mean IFN-g concentrations were comparable between the vaccinated and unvaccinated groups at 1, 2, 3, 4, 5, and 12 received related donor allogeneic marrow survived for 1 year; 4 patients had herpes zoster. One of 2 recipients of matched, months after transplantation (table 2) . IFN-g production was significantly higher beginning at 3 months after transplantation unrelated donor marrow survived for 1 year and did not develop herpes zoster. in PBMC from both vaccinated and unvaccinated patients com-/ 9d31$$se30 07-10-97 12:46:04 jinfa UC: J Infect NOTE. Cytokine data are pg/mL (mean { SE).
The interval to the occurrence of herpes zoster in unvaccito moderate and none of the vaccinated patients developed postherpetic neuralgia, whereas the intensity of acute pain was nated BMT patients was 2 -12 months. The incidence of herpes zoster was 31% in 16 unvaccinated patients who survived for mild to moderate or severe in unvaccinated patients and 4 had postherpetic neuralgia. One vaccinated patient with a history at least 12 months. Two of 8 autologous transplant patients who survived for at least 1 year and 3 of 8 survivors given of gentamicin toxicity and a cavernous sinus mass had Ramsay Hunt syndrome associated with 3 vesicular lesions in the ear allogeneic bone marrow from a related donor had herpes zoster. The 1 recipient of matched, unrelated donor marrow died 6 that were positive for VZV by direct immunofluorescence. Pathologic evaluation of the mass was inconclusive, and clinimonths after BMT without developing herpes zoster.
As shown in table 3, the clinical manifestations of herpes cal signs improved after surgical severance of the vestibular nerve, but resolution of seventh nerve palsy was incomplete. zoster were much less severe in vaccinated patients. The number of cutaneous lesions ranged from 3 to 24 in vaccine recipiNo other vaccinee required hospitalization, while 3 of 5 unvaccinated patients were admitted for intravenous acyclovir therents, and only 1 patient had fever, which lasted õ1 day. Among unvaccinated patients, the number of lesions ranged from 100 apy to control VZV reactivation.
Safety and tolerability of inactivated varicella vaccine.
No to ú500, and 3 had fevers for 1, 3, and ú7 days, respectively. Among vaccinees, the intensity of acute pain ranged from none serious adverse effects were observed with the administration T cells of the type 1 subgroup (Th1) produce IL-2 and IFNthe injection site. Of the 24 patients randomized to receive vaccine in the three-dose study, 1 patient was dropped before g, while CD4 T cells of the type 2 subgroup (Th2) release IL-4, -5, -6, -10, and -13 [24] . Whereas IL-4 production was not vaccination for fever of unknown origin, and 1 patient withdrew after receiving two doses of vaccine because of relapse detected, IL-10 release by PBMC was observed consistently after BMT and was highest in patients who recovered T cell of malignancy. None of 3 patients who died of BMT complications before completing the regimen had adverse reactions to recognition of VZV antigen, suggesting an antigen-specific enhancement of its production. The reconstitution of the Th1 the vaccine. Among patients completing the three-dose series, 1 experienced headache after the first vaccination and 1 had response to VZV in BMT patients is likely to be particularly important, because local IFN production has been correlated local erythema and swelling after the third injection. Three patients had pain at the injection site: 1 patient experienced with more rapid resolution of cutaneous lesions and IFN-g induces clonal expansion of cytotoxic T cells [19] . As observed concurrent injection site pain and headache after the first vaccination and injection site pain only after the second vaccination;
by Walter et al. [20] , cytotoxic T cell function was not sustained well after adoptive transfer of CD8 T cells in BMT patients 1 patient experienced injection site pain, muscle ache, and joint pain after the first and third vaccinations; and 1 patient who lacked CD4 T cells specific for HCMV. In contrast to cellular immunity, VZV IgG antibody titers were not a surroexperienced muscle ache and joint pain after the first vaccination and the same symptoms with injection site pain after the gate marker for risk or severity of herpes zoster in BMT recipients. This observation is consistent with previous evidence that third dose.
humoral immunity does not correlate with VZV reactivation in immunocompromised patients [25] .
Discussion
Immunization of BMT patients against herpesviruses represents a particular challenge, because disease is usually due to This study is the first demonstration that host responses to a human herpesvirus can be reconstituted by active immunizathe reactivation of endogenous viruses rather than to new exposures, and most recurrent disease occurs during the first tion of persons who have a diminished capacity to preserve latency and that vaccine-induced immunity confers protection several months after transplantation. Our evaluation of the single-dose regimen of varicella vaccine showed that shortfrom progressive disease due to virus reactivation. The pathogenesis of VZV reactivation from latency in dorsal root ganglia term immunologic enhancement did not result in clinical benefit. In contrast, the three-dose regimen boosted cell-mediated requires induction of viral genes that allow the virus to enter a replicative cycle. When reactivation occurs, immunologic immunity and modified the clinical course of herpes zoster. Optimal reconstitution of immunity to other pathogens, insurveillance is predicted to determine whether infection progresses locally and whether symptomatic disease results [17, cluding tetanus, pneumococci, Haemophilus influenzae type b, and polioviruses, has been achieved with multidose regi-18]. Long-term memory immunity to VZV is characterized by helper CD4 T cell responses and by cytotoxicity against virusmens after BMT [26 -36] . Sustaining the host response by repeated doses is likely to be necessary to preserve clinical infected cells mediated by CD4 and CD8 T cells (reviewed in [19] ). In a recent study, Walter et al. [20] documented the efficacy against herpesvirus reactivation while immunosuppressive therapy continues. importance of cellular immunity for restricting the pathogenicity of HCMV in BMT patients by using adoptive immunotherOur assessment of the inactivated varicella vaccine showed that a noninfectious, whole virus vaccine induced a functional apy with donor-derived, cloned CD8 T cells specific for HCMV. Our evaluation of inactivated varicella vaccine in BMT enhancement of antiviral immunity in immunosuppressed patients. This observation supports the concept that subunit vacpatients demonstrates that reconstitution of cellular immunity to VZV can be elicited by active immunization in the immedicines against other herpesviruses, such as the glycoprotein vaccines that are being developed for herpes simplex virus and ate posttransplant period. The impact of immune enhancement observed after active immunization of BMT recipients upon HCMV, may modify the risk of recurrent disease in BMT patients or other immunocompromised populations [37, 38] . recurrent disease establishes the critical role of virus-specific T cell responses in preserving the balance between VZV and Recovery of VZV immunity in BMT recipients may be improved further by immunizing donors and recipients before the host.
In BMT patients, IFN-g production was associated with the allogeneic transplantation, by vaccinating autologous transplant recipients before and after BMT, or by initiating the vaccine recovery of T cell proliferation to VZV antigen and increased with time following transplantation. IFN-g production by T regimen at a shorter interval after transplantation. Vaccination of donors with tetanus and diphtheria toxoids or with H. incells stimulated with VZV has been observed in healthy sub-
